---
document_datetime: 2024-01-09 11:41:40
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/koselugo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: koselugo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.6096374
conversion_datetime: 2025-12-28 19:11:19.431265
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Koselugo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                       |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------|
| PSUSA/10936 /202304  | Periodic Safety Update EU Single assessment - selumetinib                                                                                           | 26/10/2023                          | n/a                                         |                                  | PRAC Recommendation - maintenance                                             |
| II/0013              | Update of sections 4.2 and 5.2 of the SmPC in order to update the recommended dosage regimen to remove the fasting state and update pharmacokinetic | 14/09/2023                          | 19/10/2023                                  | SmPC, Annex II and PL            | For more information, please refer to the Summary of Product Characteristics. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | information, based on the final results from study D1346C00015; this is a phase 1, single-arm, sequential study to evaluate the effect of food on the gastrointestinal tolerability and pharmacokinetics of selumetinib after multiple doses in adolescent children with neurofibromatosis type 1 (NF1) related plexiform neurofibromas (PN). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0010              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 30/03/2023 | 31/05/2023 | SmPC, Annex II and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Koselugo, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| PSUSA/10936 /202210 | Periodic Safety Update EU Single assessment - selumetinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/05/2023 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| N/0012              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 13/01/2023 | 31/05/2023 | PL                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| PSUSA/10936 /202204   | Periodic Safety Update EU Single assessment - selumetinib                                                                                                                                                                                                                                                                                      | 27/10/2022   | n/a        | PRAC Recommendation - maintenance   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------------------|
| II/0006/G             | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 13/10/2022   | n/a        |                                     |
| IA/0009               | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                            | 30/08/2022   | n/a        |                                     |
| N/0008                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                               | 18/07/2022   | 31/05/2023 | PL                                  |
| N/0005                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                               | 29/06/2022   | 31/05/2023 | PL                                  |
| PSUSA/10936 /202110   | Periodic Safety Update EU Single assessment - selumetinib                                                                                                                                                                                                                                                                                      | 05/05/2022   | n/a        | PRAC Recommendation - maintenance   |
| R/0003                | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                        | 24/02/2022   | 25/04/2022 | Annex II                            |
| IB/0002               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                  | 19/10/2021   | 25/04/2022 | Annex II                            |

<div style=\"page-break-after: always\"></div>

| IB/0001   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data   | 03/08/2021   | n/a   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|